Core Insights - The report highlights a significant decline in pig prices, with the average price of live pigs dropping to 12.82 yuan/kg by September 19, marking a three-year low [5][6] - The report indicates that the supply side is experiencing pressure due to increased market supply, while demand remains weak, particularly affected by high temperatures in August [5][6] - The government is implementing stricter policies to control pig production capacity, aiming to stabilize prices and promote high-quality development in the industry [6] Industry Overview - In August 2025, the average prices for piglets, live pigs, and pork were 33.63 yuan/kg, 14.35 yuan/kg, and 24.98 yuan/kg, respectively, showing month-on-month declines of 5.87%, 3.77%, and 1.52% [5] - The report notes that the number of breeding sows in July was 40.42 million, with a slight decrease, indicating a trend of capacity reduction in the industry [5] - The report anticipates that the short-term pressure on pig prices will lead to a long-term upward trend as the government’s capacity reduction policies take effect [6] Company Insights - Major companies in the pig farming sector, such as Muyuan Foods and Wens Foodstuff Group, reported significant declines in sales prices in August, with average sales prices of 13.51 yuan/kg and 13.90 yuan/kg, respectively [7] - The report suggests that companies with strong cost advantages are likely to maintain profitability despite the current market pressures [6] - The report recommends focusing on leading companies in the industry, such as Muyuan Foods and Wens Foodstuff Group, which are expected to perform well in the long term [6]

Market Overview - The chemical pharmaceutical sector increased by 0.39% on September 25, with Aosaikang leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Top Gainers in Chemical Pharmaceutical Sector - Aosaikang (002755) closed at 23.28, up 10.02% with a trading volume of 126,300 shares and a turnover of 286 million [1] - Guangshengtang (300436) closed at 121.57, up 9.37% with a trading volume of 235,500 shares and a turnover of 2.802 billion [1] - Naimi Technology (688690) closed at 27.99, up 6.02% with a trading volume of 94,700 shares and a turnover of 26.1 million [1] Top Losers in Chemical Pharmaceutical Sector - Mengke Pharmaceutical (688373) closed at 8.61, down 10.96% with a trading volume of 717,800 shares [2] - Borui Pharmaceutical (688166) closed at 66.41, down 8.40% with a trading volume of 239,000 shares [2] - Haichen Pharmaceutical (300584) closed at 57.90, down 5.95% with a trading volume of 103,000 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 858 million from institutional investors, while retail investors saw a net inflow of 538 million [2] - The top stocks by net inflow from institutional investors included Guangshengtang with 325 million and Aosaikang with 97.5934 million [3] - Retail investors showed significant interest in Aosaikang, with a net outflow of 66.8017 million [3]

恒生港股通创新药指数通过在编制方案中剔除CXO，成为ETF跟踪的指数中首批"纯度"100%的创新药 指数，更加精准地反映我国创新药企的整体表现。目前，恒生创新药ETF（159316）是市场唯一跟踪该 指数的产品，可助力投资者精准布局创新药产业发展机遇。 昨日，恒瑞医药宣布与全球制药公司Glenmark达成独家许可协议，将其自主研发的HER2 ADC药物瑞康 曲妥珠单抗(1811)在除中、美、欧、日等核心市场外的全球权益授权给Glenmark，并收取1800万美元首 付款及最高10.93亿美元的潜在里程碑付款。 有分析认为，恒瑞医药HER2 ADC药物的海外授权交易证明中国创新药企已具备全球竞争力，此次交易 打破了近期创新药板块缺乏BD事件催化的平淡局面，加之即将到来的欧洲肿瘤内科学会及第四季度传 统BD交易高频期，市场对后续BD事件预期升温，有望开启新一轮创新药行情。 港股创新药板块午后维持红盘震荡，截至14:45，恒生港股通创新药指数上涨0.6%，云顶新耀涨超5%， 乐普生物-B涨超3%，康方生物、恒瑞医药等多股涨超1%，此前连续3日"吸金"的恒生创新药ETF （159316）盘中再获2100万份净申购。 ...

Group 1 - The innovative drug sector in A-shares and H-shares continues to rise, with notable stocks such as Aosaikang and Junshi Biosciences showing significant gains [1] - Aosaikang's subsidiary has completed the first patient dosing in a Phase III clinical trial for a new drug targeting advanced non-small cell lung cancer [1] - Heng Rui Medicine has licensed its innovative drug to Glenmark Specialty for an upfront payment of $18 million and potential milestone payments totaling up to $1.093 billion [1] Group 2 - The Hong Kong innovative drug ETF (513120) has seen a rise of over 1%, with leading stocks like Junshi Biosciences and Rongchang Bio leading the gains [2] - The innovative drug ETF (515120) has also experienced a nearly 2% increase, with significant inflows totaling 699 million yuan over the past 20 trading days [2] - Tianfeng Securities highlights that the Chinese innovative drug industry is forming a pyramid structure led by top enterprises, indicating strong sustainability in the sector [2] Group 3 - The Hong Kong innovative drug ETF (513120) allows T+0 trading, enhancing liquidity and capital efficiency for investors [3] - The innovative drug ETF (515120) closely tracks the innovative drug industry index in A-shares, covering various aspects of drug development and sales [3]

Group 1 - The Ministry of Commerce and eight other departments issued a notice to promote service exports, emphasizing the support for digital services, high-end design, R&D, and green services [1] - The Ministry of Industry and Information Technology and six other departments released a work plan for the construction materials industry, prohibiting new capacity and implementing risk warnings [1] - The People's Bank of China will conduct a 600 billion yuan MLF operation on September 25, with a net injection of 300 billion yuan, marking the seventh consecutive month of increased operations [1] Group 2 - The Ministry of Commerce announced a roundtable meeting in New York with Chinese-funded enterprises in the U.S., discussing business conditions and cooperation [1] - The Ministry of Housing and Urban-Rural Development reported that 21,700 urban old residential communities were renovated in the first eight months of the year, with a target of 25,000 by 2025 [1] - The State Administration for Market Regulation is soliciting public opinions on the basic requirements for food delivery platform service management [1] Group 3 - Alibaba Group's CEO stated that the company is committed to an open-source approach and is advancing a 380 billion yuan AI infrastructure construction plan [1] - Shanghai Zhiyuan Hengyue Technology Partnership plans to acquire 149 million shares of a company, representing 37% of its total equity, at a price of 7.78 yuan per share [1] - The carbon emissions trading market in China has seen a cumulative transaction volume of nearly 700 million tons and a transaction value of approximately 48 billion yuan as of the end of August [1]

Core Insights - Heng Rui Medicine has licensed its innovative drug SHR-A1811 to Glenmark Specialty for an upfront payment of $18 million, with potential milestone payments up to $1.093 billion [1] - The agreement grants Glenmark exclusive rights to develop and commercialize SHR-A1811 outside of 15 countries, including China, the US, Canada, Europe, and Japan [1] - The licensing deal is expected to enhance the global market reach of SHR-A1811 and improve Heng Rui's innovative brand and overseas performance [1] Product Development and Regulatory Status - SHR-A1811 has received orphan drug designation from the FDA for gastric cancer and gastroesophageal junction adenocarcinoma, and is set to be approved in China by May 2025 [1] - The drug has nine indications included in the breakthrough therapy list by the National Medical Products Administration, covering various cancers such as non-small cell lung cancer, breast cancer, and colorectal cancer [2] Company Performance and Recent Deals - Heng Rui Medicine has recently secured significant licensing agreements, including a $65 million upfront payment from BraveheartBio for another project, and a $500 million upfront payment from GSK for global rights to a different drug [2] - The company reported a revenue of 15.761 billion yuan for the first half of 2025, a year-on-year increase of 15.88%, and a net profit of 5.051 billion yuan, up 34.63% year-on-year [3]

Group 1 - The China Innovation Drug Industry Index (931152) has increased by 1.12%, with notable stock performances from companies such as Aosaikang (002755) up 10.02%, Jiuzhou Pharmaceutical (603456) up 6.41%, and Xinlitai (002294) up 4.43% [1] - Heng Rui Medicine announced a licensing agreement for its innovative drug SHR-A1811 with Glenmark Specialty, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, along with royalties based on sales [1] - According to Zheshang Securities, the domestic innovative drug sector in China is entering a phase of "engineer dividend" realization, with increasing recognition from multinational pharmaceutical companies (MNCs) leading to more frequent license-out transactions [1] Group 2 - Tianfeng Securities highlights that the Chinese innovative drug industry has formed a pyramid structure led by top enterprises, supported by a large number of quality companies, indicating strong sustainability in industry realization [2] - The underlying logic of the current cycle is that innovative drugs under development in China possess global competitiveness, with a shift from domestic sales to international data and transaction realization (license-out BD), opening up commercial space and leading to a healthier and more mature ecosystem [2] - The Jianxin Zhongzheng Innovation Drug ETF (159835) closely tracks the China Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [8]. Core Insights - The company is accelerating its international expansion, having licensed its innovative drug SHR-A1811 to Glenmark Specialty for an upfront payment of $18 million, with potential milestone payments and sales royalties totaling up to $1.093 billion. This marks the second significant overseas licensing deal for the company within the month [5][6]. - The drug SHR-A1811 has been approved for use in treating adult patients with HER2-mutated non-small cell lung cancer (NSCLC) and is the first Chinese-developed antibody-drug conjugate approved for this indication. The company is also pursuing new indications for breast cancer treatment [5]. - The company is enhancing its R&D capabilities and integrating into the global innovation network by collaborating with multinational pharmaceutical companies and innovative startups, aiming to maximize product value through international partnerships [5]. Financial Summary - The company’s projected financials for 2024 to 2027 show a steady increase in total revenue, from 27,985 million yuan in 2024 to 42,378 million yuan in 2027. Net profit is expected to rise from 6,337 million yuan in 2024 to 9,629 million yuan in 2027, with EPS projected to grow from 0.95 yuan in 2024 to 1.45 yuan in 2027 [6]. - The company’s return on equity (ROE) stands at 7.88%, with a market capitalization of 465.334 billion yuan and a closing price of 70.11 yuan as of September 24, 2025 [3][5].

Core Insights - The healthcare indices in Hong Kong have shown positive performance, with the Hang Seng Healthcare Index rising by 0.67% and the Hang Seng Innovation Drug Selection Index increasing by 0.74% as of September 25, 2025 [3][5] - Notable stock performances include a 6.57% increase in Crystal Technology Holdings and a 6.41% rise in Junshi Biosciences [3][5] - The liquidity of the ETFs tracking these indices is robust, with significant trading volumes and turnover rates [3][5][7] ETF Performance - The Hang Seng Healthcare ETF (513060) has seen a 27.42% increase over the past three months, ranking in the top third among comparable funds [3] - The Hong Kong Innovation Drug Selection ETF (520690) has recorded a 2.63% increase since its inception [5] - The Medical 50 ETF (159838) has increased by 2.19% over the past month, ranking in the top half among comparable funds [7] Company Developments - Heng Rui Medicine has entered an overseas licensing agreement with Glenmark for the drug Rukang Qumai (HER2 ADC), which includes an upfront payment of $18 million and potential milestone payments and sales royalties totaling nearly $1.1 billion, indicating international recognition of its ADC products [7][8] - The National Healthcare Security Administration is actively seeking information on innovative medical consumables such as brain-computer interfaces and surgical robots, aiming to accelerate the coding process for medical insurance and support the commercialization of innovative medical devices [7][8] Market Sentiment - The dual boost from the international licensing agreement and proactive government engagement in innovative technologies is expected to enhance sentiment in the healthcare sector, particularly for companies with technological barriers in ADCs, surgical robots, and brain-computer interfaces [8]

另外，生物医药ETF（159859）在昨日收涨超1.3%的基础上，今日继续上涨，截至发稿涨幅为1.13%， 盘中频现溢价交易。 生物医药ETF（159859）紧密跟踪生物医药指数。国证生物医药指数以A股市场属于生物医药产业相关 上市公司为样本空间，根据市值规模和流动性的综合排名，选出前30只股票作为指数样本股（数量不足 时则按实际数量选入），反映了生物医药行业的整体运行情况该ETF还配备了联接基金（A：011040， C：011041）。 消息面上，创新药龙头之一恒瑞医药近期传来利好消息。 9月25日早间，A股三大指数涨跌不一，部分医药股表现活跃；港股医药生物板块涨幅居前。相关ETF 中，创新药ETF天弘（517380）延续反弹，截至发稿涨1.74%，溢折率0.25%，盘中溢价交易明显。成 分股中，奥赛康、九洲药业涨停，港股君实生物、港股荣昌生物等跟涨。 浙商证券认为，中国本土创新药进入"工程师红利"兑现期，中国本土创新药已经得到MNC充分认 可。"工程师红利"下，更高效临床效率，更优异/优效的临床数据等优势，持续强化本土创新药未来确 定性的国际化/BD以及估值突破前景。 创新药ETF天弘（517380）是全 ...